NR4A1 and breast carcinoma: Indeed, the effects of lumican seem to be hormone-receptor dependent as the aggressive metastatic ERβ-positive MDA-MB-231, the ERβ-suppressed (shERβMDA-MB-231) cells, and the ERα-positive MCF-7/c breast cancer cells of a low metastatic ability exhibit varying responses to lumican.